Risk factors
Evommune (EVMN) risk factors
Item 1A of every Evommune, Inc. 10-K on file, and what changed from one year to the next. Readings are automated and can be wrong; check the filing for the exact wording.
- FY2025 10-K risk factors88 risks
Evommune faces substantial execution and financing risks to develop and commercialize its lead product candidates EVO756 and EVO301. Clinical trial success, regulatory approvals, and third-party reimbursement are uncertain hurdles for long-term profitability. The company relies heavily on a small team of 48 employees and external contractors.
Filed Mar 05, 2026